Fairchem Organics Q2 FY27: PAT ₹10 & Rev ₹176 Cr

Metric	Value
Revenue	₹176 Cr
Net Profit (PAT)	₹10

📢 Key Event
Fairchem Organics reported Q1 FY2027 revenue of ₹176 crores, up 34.4% YoY, with EBITDA margin at 10.14% and net profit of ₹10 crores.

🔄 What Changed
Revenue grew 34.4% YoY to ₹176 crores; EBITDA margin held at 10.14%; net profit reached ₹10 crores; capacity utilization increased to 60% with target of 70-75% by FY27; Isostearic acid sales share remains at 4% amid commercialization delays.

🔮 What's Next
Target capacity utilization of 70-75% by FY27; 5-7% quarterly growth; 15-20% YoY growth; new 40,000 MT oleochemical capacity; Isostearic acid ramp-up delayed by cosmetics barriers; no debt-funded expansion.

💡 Investor Takeaway
Fairchem is growing revenue rapidly but faces margin pressure from trade and input costs, with capacity expansion tied to organic growth and regulatory hurdles in new markets.

Fairchem Organics reported Q1 FY2027 revenue of ₹176 crores, up 34.4% YoY, with EBITDA margin at 10.14% and net profit of ₹10 crores. Capacity utilization rose to 60% from ~60% previously, targeting 70-75% by FY27. Isostearic acid contributes 4% of sales and is in advanced commercialization, though cosmetics entry barriers delay ramp-up. Export revenue remains low at 7-8%, supported by trade agreements. The company emphasizes organic growth without debt, with 40% revenue concentration in paint and plans for 40,000 MT new capacity. Margin pressure from inverted duties and geopolitical risks persist, but supply constraints have eased. Management highlights sustainable growth and regulatory advantages in key markets.

📄 View Original Announcement (PDF)

📊 Stock Analysis — FAIRCHEMOR ✨ Ask AI About This

About Fairchem Organics Limited (FAIRCHEMOR)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹778.49 Cr P/E: 140.5

View full FAIRCHEMOR stock details →

📡 Get AI alerts when FAIRCHEMOR files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track FAIRCHEMOR — Free

💡 Ask AI about this filing

"How will Isostearic acid commercialization impact revenue and margins by FY28?" "What is the expected revenue contribution from the new 40,000 MT capacity by FY29?" "How does Fairchem plan to mitigate inverted duty risks affecting future margins?"

Ask AI Free →

📊 More FAIRCHEMOR filings

See all FAIRCHEMOR filings →

🔥 Also filed on 30 July 2026

SYRMA Syrma SGS Technology Limited Offer Document AYMSYNTEX AYM Syntex Limited Announcement AJANTPHARM Ajanta Pharma Limited Corporate Action GATEWAY Gateway Distriparks Limited Corporate Action PARADEEP Paradeep Phosphates Limited Financial Results GILLETTE Gillette India Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FAIRCHEMOR files new disclosures

Track FAIRCHEMOR filings, board meetings, and corporate actions. Free email alerts at 5 PM.